CatenaBio’s Post

At CincyTech, we are bullish on the regional life sciences ecosystem. The below report helps illustrate why. CC: Ohio Life Sciences

What gets interesting here is when you start to consider the value chain of research to real🚶♀️life impact, and this region spans that chain from: - research at top institutions Cincinnati Children's University of Cincinnati - to seed investment (including CincyTech and Orange Grove Bio) and growth investment RC Capital - to the clinical trial companies like Medpace and CTI Clinical Trial and Consulting Services - to the manufacturing capabilities known as a staple of the Midwest region in a new light (with companies like Resilience, Expression Therapeutics, Inc. Meridian Bioscience Inc. and even Enable Injections, Inc. manufacturing themselves) - the diagnostic testing available Gravity Diagnostics Myriad Genetics and devices in market or "baking" to change the standard of care Eyas Medical Imaging Genetesis, - and patient care at numerous well regarded hospital systems including the #1 US pediatric hospital, Cincinnati Children's, and well distributed healthcare access and reach through Kroger Health. Sprinkle in the statistic that 60% of the US population lives within an ~8 hour drive of Cincinnati, and think about the extended supply chain possibilities and ACCESS TO CARE that #Cincinnati enables. #lifesciences #funfactfriday

💭 Despite new technologies emerging and existing techniques being refined, there is a critical need for biophysicists focusing on early-stage drug discovery to come together, share innovative ideas, and harness transferrable lessons to inform efficient drug discovery. The 𝗕𝗶𝗼𝗽𝗵𝘆𝘀𝗶𝗰𝘀 𝗳𝗼𝗿 𝗗𝗿𝘂𝗴 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 𝗦𝘂𝗺𝗺𝗶𝘁 provides a forum for exactly that, have you secured your pass yet? ⏳ This week only you can 𝘀𝗮𝘃𝗲 𝘂𝗽 𝘁𝗼 $𝟴𝟱𝟬 𝗼𝗻 𝘆𝗼𝘂𝗿 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 – and that doesn’t include the discounts for bringing a colleague! But hurry, this discount expires Friday, February 9! With representatives from across the industry having confirmed their participation, this is you and your teams exclusive opportunity to immerse yourself in critical discussions on innovative applications of biophysical techniques to unlock maximum insights into molecular and target interactions. Secure your pass here: https://ter.li/m1dpy4 👩🏫 Want to share your own work? Included in your ticket is the opportunity to demonstrate your own innovations at our dedicated poster session, find out more here: https://ter.li/biophysics #biophysics #drugdiscovery #drugdesign #drugdevelopment #biophysicists

Check out the latest Outcome index tracker, transaction highlights, and strategic analysis from Outcome Capital's #lifesciences deal team. - Targeted protein degradation therapies, in the form of molecular glues or degrader antibody conjugates, continue to catch the eye of both investors and #biopharma partners as an alternative form of #cancertherapeutics - Ginkgo Bioworks completes #diagnostics spending spree through a flurry of #acquisitions to strengthen foothold in genetic medicine capabilities - Fractyl Health breaks #medtech public market drought with #ipo debut - #strategicinsights from Outcome Capital industry expert on Viking Therapeutics, Inc. potential to shake up the #glp1 market and dethrone #pharmaceutical giants currently dominating obesity drug race 

We are excited to share how Crystal Pharmatech utilizes PBPK modeling for the fastest and most efficient formulation development. Register to attend!   Subject Matter Expert, Ridwan Islam, M. Pharm., Ph.D., will present: “Utility of PBPK Modeling as Step 1 in a 3-Step First Time Right Crystal Pharmatech Formulation”   Abstract: PBPK modelling is a valuable tool to address a much wider range of pharmaceutical applications besides drug-drug interactions. We present here PBPK modeling applications routinely used at our CDMO for in-vitro to in-vivo translation and pharmacokinetic modelling in preclinical species in addition to first-in-human pharmacokinetic predictions. Linking of in-silico quantitative structure–property relationship models with (PBPK) modelling is Step 1 of a tailored Formulation for Phase I. Combined with parameter sensitivity we can clearly identify the key compound API Form and Formulation properties. This leads to the fastest, most efficient formulation development with visibility into future clinical trials.

Next chapter for Sapreme!

Looking forward to seeing some known faces and meeting some new ones! Investing? How commercially viable is the science? What are the product development/CMC and regulatory risks? What is the competitive landscape? Fundraising? Does your pitch deck and data room position your company to be as investable as possible? Promising non-clinical data? How to turn that into a commercial product? What is the best product development and regulatory strategy? Growing pains? Addressing the various resource gaps in regulatory affairs, regulatory operations, clinical operations, clinical and medical affairs, regulatory and medical writing and many more as you transition the product from one phase to another! It has been great to work with innovators and the leaders to help them advance their asset and materialize the vision! Looking forward to connecting further to brainstorm solutions with you! #TexasLifeSciencesSummit #CPRIT #THBI

A learning opportunity.

❗ Only 7 spots left ❗ Make sure you book your seat for the COMBINE #Webinar to hear & learn from Target Product Profile experts in the #antibiotic field before it's too late. You can't make it? No worries! We'll have the webinar recorded for you 👀 https://lnkd.in/ezauwdYr #AMR #DrugDevelopment #AntimicrobialResistance

Why should you attend ICMS® in Boston? Here’s a word of advice from Principal Scientist Edward Humphries, a frequent ICMS attendee: “𝗔𝘀 𝗮𝗻 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹 𝗯𝗶𝗼𝗹𝗼𝗴𝗶𝘀𝘁 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝗶𝗻 𝗱𝗿𝘂𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆, 𝗜𝗖𝗠𝗦 𝗶𝘀 𝗮 𝗺𝘂𝘀𝘁-𝗮𝘁𝘁𝗲𝗻𝗱 𝗲𝘃𝗲𝗻𝘁 𝗳𝗼𝗿 𝗺𝗲 𝗲𝘃𝗲𝗿𝘆 𝘆𝗲𝗮𝗿. 𝗧𝗵𝗲 𝗹𝗲𝗰𝘁𝘂𝗿𝗲𝘀 𝗰𝗼𝘃𝗲𝗿 𝗮 𝘄𝗶𝗱𝗲 𝗿𝗮𝗻𝗴𝗲 𝗼𝗳 𝘁𝗼𝗽𝗶𝗰𝘀, 𝗳𝗿𝗼𝗺 𝗶𝗻-𝗱𝗲𝗽𝘁𝗵 𝗲𝗹𝗲𝗰𝘁𝗿𝗼𝗽𝗵𝘆𝘀𝗶𝗼𝗹𝗼𝗴𝘆 (𝘄𝗲 𝗲𝘃𝗲𝗻 𝘀𝗮𝘄 𝘀𝗼𝗺𝗲 𝘀𝗶𝗻𝗴𝗹𝗲-𝗰𝗵𝗮𝗻𝗻𝗲𝗹 𝗿𝗲𝗰𝗼𝗿𝗱𝗶𝗻𝗴𝘀 𝗹𝗮𝘀𝘁 𝘆𝗲𝗮𝗿) 𝘁𝗼 𝗯𝗿𝗼𝗮𝗱𝗲𝗿 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝘂𝗽𝗱𝗮𝘁𝗲𝘀 𝗳𝗿𝗼𝗺 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗹𝗶𝗸𝗲 𝗔𝘀𝘁𝗿𝗮𝗭𝗲𝗻𝗲𝗰𝗮 𝗮𝗻𝗱 𝗔𝘂𝘁𝗶𝗳𝗼𝗻𝘆 𝗶𝗻 𝗿𝗲𝗰𝗲𝗻𝘁 𝘆𝗲𝗮𝗿𝘀. 𝗪𝗼𝗿𝗸𝗶𝗻𝗴 𝗮𝘁 Maxion Therapeutics, 𝗮𝗻 𝗶𝗼𝗻 𝗰𝗵𝗮𝗻𝗻𝗲𝗹 𝗮𝗻𝗱 𝗚𝗣𝗖𝗥-𝘁𝗮𝗿𝗴𝗲𝘁𝗶𝗻𝗴 𝗱𝗿𝘂𝗴 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗰𝗼𝗺𝗽𝗮𝗻𝘆, 𝗜𝗖𝗠𝗦 𝗽𝗿𝗼𝘃𝗶𝗱𝗲𝘀 𝗮 𝗴𝗿𝗲𝗮𝘁 𝘄𝗮𝘆 𝘁𝗼 𝗺𝗲𝗲𝘁 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗼𝗿𝘀 𝗮𝗻𝗱 𝗹𝗲𝗮𝗿𝗻 𝗳𝗿𝗼𝗺 𝗹𝗲𝗮𝗱𝗶𝗻𝗴 𝗮𝗰𝗮𝗱𝗲𝗺𝗶𝗰𝘀 𝗶𝗻 𝗮 𝗿𝗲𝗹𝗮𝘅𝗲𝗱, 𝗶𝗻𝘁𝗶𝗺𝗮𝘁𝗲 𝘀𝗲𝘁𝘁𝗶𝗻𝗴 𝘄𝗵𝗲𝗿𝗲 𝗶𝗱𝗲𝗮𝘀 𝗳𝗹𝗼𝘄 𝗮𝗻𝗱 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽𝘀 𝗮𝗿𝗲 𝗰𝗿𝗲𝗮𝘁𝗲𝗱.” If you haven't registered for the event, you can sign up now here: https://ow.ly/wP6h50SC63a Our ICMS® brings together researchers, scientists, and industry professionals from around the world to exchange ideas, share the latest advancements, and explore new frontiers in ion channel modulation. The event will feature keynote speakers, poster presentations, and excellent networking opportunities. We look forward to spending two days together filled with inspiring talks and discussions. Don't miss out – sign up now while seats are still available. The symposium fills up quickly. #ICMS #Qube384 #QPatch #QPatchCompact #AutomatedPatchClamp #IonChannels #DrugDiscovery #Electrophysiology #Sophion